We’re five years in, so what does the CBD industry look like now and what can we expect in 2023? We spoke with several CBD experts who walked us through the highs and lows of 2022.
The recent raft of warning letters to brands selling CBD-infused foods and beverages marked a shift in FDA approaches to the ingredient, with the Agency seeming to opine that food and beverages are “somehow a greater risk than supplements”.
The FDA has sent out a raft of warning letters to brands selling CBD-infused foods and beverages, adopting an “aggressive position” that one industry source told us made him “concerned for our entire industry.”
“I see all these emails going around saying once the [2018] Farm Bill passes, CBD is legal in all 50 states… and that’s just not true,” observed one attorney in December 2018. Four years later, while a lot has changed, the FDA maintains that CBD is not...
After dominating the UK CBD space with help from a highly engaged online fanbase, CBD beverage, oil and gummy brand Trip is hoping to cement a similar position in the US – but this time with the additional aid of $12m in funding from prominent entrepreneurs...
The American Herbal Products Association has released a new guidance document that seeks to bring clarity to hemp nomenclature, in particular what ought to be meant by the terms ‘broad spectrum’ and ‘full spectrum’ extracts.
Legislation currently in the Senate could burden the hemp industry by setting an unrealistically low level of allowable THC, an industry group has said.
Iowa-based Kemin is expanding its portfolio to introduce a range of USDA-certified organic, traceable, U.S.-grown hemp CBD distillates for use in health and wellness products.
FDA came down hard on purveyors of Delta-8 THC and CBD products that were making disease claims on the substances. The Agency also reiterated the reasons it believes Delta-8 is not a suitable ingredient for products marketed as supplements.
The hemp/CBD market is going through a reckoning but ultimately will emerge in a stronger position, said the head of one of few publicly traded companies in the sector.
The United States Pharmacopeia (USP) has published a commentary raising potential safety and quality control concerns about the delta-8 THC products flooding the market. The document also raised issues with other cannabinoids that are being isolated...
The California Legislature has passed a bipartisan bill to establish rules for the production and marketing of CBD/hemp products. Proponents expect Gov. Gavin Newsom to sign the bill into law before the Oct. 10 deadline.
The US Food and Drug Administration has rejected two New Dietary Ingredient Notifications for CBD ingredients. Industry stakeholders said the fact of the rejections and some of wording used in the letters makes it clear that new legislation is likely...
A bill put forward by Senate Majority leader Chuck Schumer, D-NY, to decriminalize marijuana includes language on CBD that has been welcomed by supplement industry stakeholders.
The publication of a recent FDA priorities list that omitted the hemp/CBD question is a reminder that a legislative solution is the only practical way forward for a regulatory resolution for these ingredients, advocates say.
A US Senate bill to specifically allow the use of CBD and other hemp derivatives in dietary supplements and foods has been introduced with bipartisan sponsorship. The bill also enjoys broad support within the industry.
CBD products manufacturer CV Sciences has recorded a sharp decline in revenue, mirroring reports of an overall contraction in the market for hemp extract products.
The state of Colorado aims to remain a leader in the hemp industry, Gov. Jared Polis said at an industry event last week. He announced the release of a detailed state plan for the industry at the meeting, which includes scientific support, data sharing,...
The CBD/hemp markets, both in finished goods and on the supply side, are in a state of transition, attendees at an industry event learned on Friday. The message was that some growers and some finished product marketers are likely to fall by the wayside...
Colorado-based ValidCare has announced the preliminary findings from its industry-sponsored, decentralized human safety study of hemp derived CBD products, with the data indicating no liver toxicity.
Yesterday the Natural Products Association testified in favor of a California bill to regulate the CBD trade in that state. NPA and others, however, have reiterated a call for federal legislation that would forestall the growing patchwork quilt of state...
Recent news reports about the marketing of products featuring Delta-8 THC as a prominent constituent have muddied the waters enough that the US Hemp Roundtable felt it necessary to clarify again what should—and shouldn’t—be called a hemp product.
Federal regulators could do more to protect consumers by using existing import authorities as well as moving forward on hemp/CBD regulation, the National Products Association has said.
GW Pharmaceuticals and supplement retailer GNC have reportedly been among the companies meeting recently with a White House division to discuss aspects of CBD regulation.
Hemp plants contain dozens of bioactive cannabinoid molecules and one of them, CBG, is starting to edge onto the main stage with its better known peer, CBD.
The hemp/CBD industry may have gotten the cart before the horse in terms of extraction capacity and raw material supply, said an investment analyst familiar with the sector.
A bill before the California State legislature would open the country’s largest market to dietary supplements and foods containing CBD, but advocates say time is running out while the machinery of state government is preoccupied with pandemic concerns.
An amendment to a military funding bill would make it possible for military personnel to openly use hemp/CBD products for the first time. While advocates welcome the development, there is little prospect that CBD products will become part of standard...
A group of hemp/CBD purveyors have teamed up with a clinical research firm to conduct a large scale study to provide the safety data that the US Food and Drug Administration says it lacks.
New claims creeping into the hemp/CBD space are indicative of the some of the unsolved regulatory issues that continue to distort the market. These include claims of ‘zero THC’ and ‘no CBD isolate.’
The state of Texas has proposed rules for consumable hemp products that specify processing, testing, labeling and registration requirements. While the rules are characterized as reasonable and well thought out, they represent another patch in a state-by-state...
It’s a tough time to launch a new CBD food or beverage brand, with COVID-19 upending timetables, trade shows cancelled, and continued regulatory uncertainty as firms wait for clarity from the FDA. However, e-commerce presents growth opportunities, and...
Consumers seem to be turning to hemp and cannabis products during the current crisis, which has buoyed the near term outlook for Curaleaf, one of the largest companies in the sector, which posted strong revenue growth in its recent annual report.
CBD firm Charlotte’s Web reported $94.6 million in revenue in its annual report and announced an acquisition that expands its distribution into topical products.
By Hank Schultz, Elaine Watson and Elizabeth Crawford
A report on CBD delivered by FDA Commissioner Dr Stephen Hahn, MD, was seen by food and dietary supplement industry stakeholders as offering little hope of a timely regulatory solution for the ingredient.
FDA Commissioner Dr Stephen Hahn, MD, in a speech on Wednesday, said that despite its continued concern about insufficient safety data, the FDA has no plans to try to shut down the CBD markets. Hahn said that would amount to a “fool’s game.”
After an explosive start in late 2019 (it sold 200,000 cans in 36 hours on Black Friday via its website) LIFEAID has secured listings in 350 Vitamin Shoppe stores (in CBD-friendly states), Lucky’s Market in Colorado, and New Seasons for its new CBD-infused...
The FDA has promised to provide more clarity over CBD “in the coming weeks.” But how should brands navigate the regulatory minefield in the meantime, and what options does the agency have?
Emboldened by a recent court ruling in Florida that stayed a CBD-related class action on primary jurisdiction grounds (ie. putting the case on ice until the FDA weighs in), multiple brands hit with similar lawsuits are now pushing for stays and referencing...
Dietary supplement industry stakeholders are divided over whether proposed legislation to alter the regulatory definitions of dietary ingredients to specifically include CBD is the best way to break the logjam on the substance.
An analysis of recent warning letters underscores the notion that FDA is focused its enforcement efforts on CBD, and is not targeting hemp extracts per se.
